Within the first treatment year there was furthermore a tendency towards a lower proportion of insulin analogues used as basal insulin supplementation in CHI patients with diabetes (20% vs. 26% in patients with T1DM, p = 0.8). This evidence concerns the gene INS and diabetes mellitus.